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ABSTRACT 
The Epidermal Growth Factor or ErbB family of receptor tyrosine kinases has 
been the focus of cancer therapeutics based on their involvement in numerous cancer 
types, including lung, breast and brain.  This pathway is conserved from humans to flies 
(Drosophila) making Drosophila a good model organism for ErbB cancer related studies.  
Toward this goal, transgenic flies were generated with ErbB3 and ErbB4 members of the 
ErbB family.  Moreover, functional studies demonstrated that ErbB4 is indeed active in 
Drosophila providing a novel avenue for research opportunities in the field of cancer 
therapeutics. 
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BACKGROUND 
Cancer, the uncontrolled growth of abnormal cells, is a major global disease. Each 
year, this disease affects millions of lives and accounts for over 10% of all deaths (World 
Health Organization, 2010). Cancer is a very difficult disease to fight because it is caused 
by a combination of numerous mutations. To worsen the situation, these mutations are 
not conserved in all types of cancers. As a matter of fact not all of these cancers have 
been characterized so it is possible that novel types of mutation are still being identified.  
In hopes of discovering potential ways to treat human cancer, researchers have embarked 
on genomic scale studies of signal cancer cells to identify signal transduction pathways 
that are perturbed. As more is deciphered about cancer, researchers are able to begin 
developing therapeutics or treatments that specifically target signaling pathways (e.g. 
ErbB) in which (hyper/hypo) regulation leads to oncogenesis.  
The ErbB family of Receptor Tyrosine Kinases 
Protein kinases are enzymes that play a major role, through signaling pathways, in nearly 
every aspect of cell biology: apoptosis regulation, cell cycle progression, cytoskeleton 
rearrangement, differentiation, development, immune response, nervous system function, 
and transcription (Roskoski, 2004). Receptor Tyrosine kinases (RTK) are a class of 
protein kinase which play a role in  regulating cell division, cellular differentiation, and 
morphogenesis. There are about 58 known different human receptor tyrosine kinases 
encoded by the human genome, which can be subdivided into 20 families (Blume-Jensen 
and Hunter, 2001). They all consist of three domains: an extracellular domain, a 
transmembrane domain, and an intracellullar domain. The extracellular domain serves as 
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the ligand binding part of the molecule. The transmembrane domain is a single α-helix 
molecule. The intramembrane domain or the cytoplasmic domain is the domain where 
highly conserved kinase activity as well as several other regulatory functions occur 
(Blume-Jensen and Hunter, 2001).     
Among the 20 sub-families of RTKs, the ErbB family is one of the most well 
characterized families of receptors. The family consists of 4 different receptors: 
Epidermal Growth Factor Receptor (EGFR/ErbB1), ErbB2, ErbB3, and ErbB4 
(Roskoski, 2004). The canonical signaling pathway for these receptors is depicted in 
figure 1 above. Like other RTKs, all these receptors have an extracellular region, a small 
transmembrane region, and an intracellular tyrosine kinase region engulfed by a 
 
 
Figure 1: ErbB/HER signaling Pathways. All together, there are 58 different human RTKs split into 20 different families.  
This figure illustrates the pathway of ErbB/ HER family members of RTKs. In the figure the pathway of each of the 4 
ErbB/HER genes can be traced.  
(Taken from: Cell Signaling Technology Inc., 2004) 
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juxtamembrane region and a carboxyl (C-) terminal tail (Burgess et al., 2003).  The ErbB 
receptors have four extracellular subdomains, I – IV, with regions II and IV being 
cysteine-rich and regions I and III being important for ligand-binding. (Burgess et al., 
2003).  
There are two forms of the ErbB receptor monomers relating to their activation.   
ErbB receptors are tethered monomers when inactive, with the extracellular region folded 
over on itself (Linggi and Carpenter, 2006).  However, they are activated through the 
binding of a ligand, such as EGF, to the receptor and the subsequent dimerization of the 
receptor as shown in figure 2 (Roskoski, 2004). Ligand binding causes two reactions: 
dimerization and trans-autophosphorylation. Ligand binding exposes the dimerization 
arms of the ErbB receptors, allowing two receptors to dimerize (Burgess et al., 2003).  
This activates the kinase activity of the receptors, which in turn causes the monomers to 
transphosphorylate tyrosine residues in their C-tail and triggers activation of the 
canonical EGFR/Ras signaling pathway in the cell (Roskoski, 2004). Triggering of the 
pathway is dependent on many additional factors, as well (Roskoski, 2004). 
 
 
Figure 2: Activation of the ErbB receptor. EGFR typically has a tethered, folded-over structure 
when inactive, but when EGF ligand binds, the EGFR opens and is able to dimerize with itself or 
another ErbB receptor.  The dimerization activates the receptor and triggers autophosphorylation of the 
C-tail tyrosine residues. 
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ErbB receptors are similar in structure but slightly different in the role they each 
play in the body. They have different ligand specificities, making them each somewhat 
unique. EGFR/ErbB1 and ErbB4 are fully functional, meeting both activation 
requirements: ligand binding and kinase activity (Burgess et al., 2003). The other two, 
ErbB2 and ErbB3, lack one of those two requirements. ErbB2 lacks ligand-binding 
activity, rendering it inactive. However it can be activated upon dimerizing with another 
ErbB family member, capable of binding to ligand (Burgess et al., 2003; Linggi and 
Carpenter, 2006).  ErbB3, on the other hand, has a functional ligand-binding region, but 
an inactive intracellular domain. In ErbB3, the tyrosine kinase domain is inactive, so it is 
unable to phosphorylate C-tail tyrosines, but can act as a substrate for the kinase domain 
of another receptor if a heterodimer is formed (Burgess et al., 2003).  It is interesting to 
note that though ErbB2 and ErbB3 are inactive independently, the ErbB2-ErbB3 
heterodimer is the most active, mitogenic and transforming RTK complex (Yarden and 
Sliwkowski, 2001). This is due to complementation of the genes. The loss of ligand 
binding in ErbB2 is compensated for by respective activity of ErbB3 and vice versa. 
Additionally, it has been suggested that EGFR/ErbB1 is able to bypass canonical 
signaling cascades and translocate to the nucleus where it can more directly regulate cell 
processes and gene expression (Technology, 2004). 
 Misregulation of the ErbB family’s signaling network has been identified as a 
potential cause of cancer in human.  Generally, cancer caused by ErbB occurs when the 
pathway becomes hyper-activated by the overproduction of ErbB receptors and the 
overproduction of ligands (Yarden and Sliwkowski, 2001).  An example of such 
mutations is the misregulation of the phosphatidylinositol-3 kinase (PI3K) and mitogen-
9 
activated protein kinase (MAPK) signaling pathways (Holbro et al., 2003; Yarden and 
Sliwkowski, 2001).   
In a normal cell, the autophosphorylation of ErbB receptors triggers the activation 
of intracellular pathways necessary for 
normal development (Yarden and 
Sliwkowski, 2001). The activation of these 
different intracellular signaling pathways as 
a result of ErbB RTK activation and 
autophosphorylation is mainly based on the 
adaptor molecules that bind to the 
phosphorylated tyrosines in the ErbB receptor 
C-tail (Batzer et al., 1994).  As shown in 
figure 3 below, both the MAPK and PI3K 
signaling cascades triggered by the ErbB receptors lead to a transcriptional responses 
controlling cell fate.  Phosphotyrosine binding proteins with SH2 or PTB domains 
commonly work as adaptors between the activated ErbB receptor and RTK signaling 
pathway (Batzer et al., 1994).  Two adaptor proteins, Shc and Grb2, provide a common 
link between the EGFR receptor and the two main signaling cascades: MAPK and PI3K 
(Batzer et al., 1994). It is proposed that Grb2 and Shc form a complex, together binding 
to specific phosphotyrosine residues on EGFR and then linking to SOS, thereby 
triggering the MAPK pathway.  It has also been proposed that PI-3K binds directly to 
phosphorylated tyrosines in ErbB3 and ErbB4 via SH2 domains on its p85 subunit, but 
 
Figure 3: Oncogenic signaling pathways 
activated by the activation of ErbB receptors.    
Binding of ligand to the receptor is responsible for 
the cross phosphorylation of the receptor dimer and 
subsequent pathway activation.  Conserved  
phosphotyrosine sequences bind to the SH2 
domains of signaling molecules which activate the 
PI3K/AKT (left) and MAPK (right) pathways which 
have been implicated in many cancers. 
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binds indirectly to EGFR through a Shc adaptor molecule, GAB1, that binds via Grb2 
(Blume-Jensen and Hunter, 2001). 
Drosophila as a Model Organism 
For over a century now, Drosophila melanogaster, commonly known as the fruit 
fly, has been used as a model experimental system for research related to developmental 
and cellular processes common to higher eukaryotes. It has also been used to test for 
potential disease treatments. Since the sequencing of both the Drosophila and human 
genomes in the 21st century, research has confirmed the conservation of a majority of 
human diseases in Drosophila (Fortini et al., 2000). To be specific, 62% of human 
disease genes have been conserved in Drosophila—boosting researchers’ confidence in 
the use of Drosophila as a model organism (Rubin et al., 2000).   
In addition, the homologous sequence of 68% of all human cancer genes has been 
recognized in Drosophila (Rubin et al., 2000). For example, the ErbB family of genes 
correlates with Drosophila EGFR gene (Rubin et al., 2000). Drosophila contains highly 
organized signaling pathways regulated by many intracellular and extracellular molecular 
signals, e.g JAK/STAT (Baeg, 2005) and the MAPK pathways (Li and Garza, 2003).  
Drosophila is important for cancer research because it gives researchers a better 
way to develop drugs. Using cellular assays like it’s normally done to screen for drugs 
avoids realistic problems like drug reactions, target expression and toxicity, but using an 
organismal approach gives researchers more confidence because it more accurately 
represents the final scenario (Manev et al., 2003). GAL4-UAS system in Drosophila 
allows for targeted expression of a gene of interest (Duffy, 2002).  Crossing responder 
(UAS) and driver (GAL4) lines enables the overexpression of a gene and the 
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corresponding phenotypic effect (eg. eye roughness) can be studied (Duffy, 2002).  Drugs 
can then be screened for their effect on these phenotypes.   
As stated earlier, the dEGFR gene in Drosophila correlates to the human ErbB 
genes and its activity functions in much the same manner as in humans. With respect to 
Drosophila development, its activity within the follicle cells determines the dorsal fates. 
The dorsal/ventral polarity of the eggshell (chorion) provides a very simple marker for 
dEGFR signalingactivity.  Specification of dorsal appendages allows the different levels 
of dEGFR activation to be approximated, allowing for easy phenotypic characterization 
of receptor activity.  Wildtype flies lay chorions with 2 dorsal appendages, while flies 
lacking EGFR activity lay ventralized chorions. In contrast, flies with hyperactive EGFR 
signaling lay dorsalized chorions, easily observed by the presence of ectopic dorsal 
appendages.  
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STATEMENT OF PURPOSE 
Cancer has been linked to the misexpression of key genes.  In particular, there is 
good evidence of linkage between the misregulation of the ErbB receptors and the 
development of certain types of cancer.  The ErbB family of receptors is crucial for 
normal development.  However, when mutated by hyperactivation and subsequent 
autophosphorylation of kinase domains, downstream signaling proteins become highly 
upregulated, promoting oncogenesis.  
Currently one common approach to treat cancer is by chemotherapy.  This is a 
very harsh way of treating cancer because it kills the cells that are growing abnormally, 
leaving patients with severe pain and loss of hair.  More specific or targeted therapeutics 
exhibiting fewer side effects would provide a better treatment alternative.  Drosophila is 
a reasonable model organism to screen for such cancer therapeutics because it shares 
most of the same receptor and intracellular signaling pathways that have been implicated 
in cancer with humans. This is perfect for cancer research because an assumption can be 
made that any cancer research done with Drosophila are likely to be able to be 
extrapolated to humans.  With the ability to generate flies transgenic for the human ErbB 
genes, it is possible to test activity of the human receptors in flies and develop simple 
feeding assays to screen for drugs that would prevent their activation and thus function as 
potential cancer therapeutics.  Thus, this project aims at determining if Drosophila could 
be used to identify new and better therapeutics for EGFR dependent cancers.    
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MATERIALS AND METHODS 
Generation & Mapping of Transgenics 
Maxiprepped DNA for the two constructs was sent to Genetic Services, Inc. (Cambridge, 
MA) to be injected into w1118 embryos. The resulting larvae were then returned to us for 
transgenic screening. Surviving flies (generation G0) were single-pair mated to either 3-4 
w1118 females or 2-3 w1118 males, depending on the sex of the transgenic. Because the 
transgene confers pigmentation to the eye for both genes, any progeny from this initial 
cross with eye color should be transgenic. Such transgenic flies (generation F1) were 
collected and separated. For putative transgenics derived from a single injected G0, 2 
single-pair matings were set up (preferably with males), again with w1118 females or 
males to amplify the number of transgenic flies on hand (generation F2). Putative 
transgenics derived from distinct G0s were considered independent insertions. Matings of 
transgenic males (P [UAS-ErbB3&4*]/+; *ErbB3&4 variant) with females of the 
genotypes w-; Sp/CyO (chromosome II) and w-; Ly/TM3, Sb (chromosome III) were set 
up for mapping purposes. Heterozygous progeny from these matings (preferably of the 
genotypes P[UAS-ErbB3&4*]/CyO or P[UAS-ErbB3&4*]/TM3, Sb) were then 
outcrossed back to w1118 to determine the segregation pattern of the transgene versus the 
marker; e.g., if the CyO phenotype consistently segregates away from the transgene, the 
transgene must be on chromosome II. Once mapped, stocks of representative transgenic 
lines were created by first mating a single P [UAS-ErbB3&4*]/+ transgenic male to 
females of its respective balancing stock (w-; Sp/CyO or w-; Ly/TM3,Sb) to ensure that 
the stock’s founding members were isogenic. Female and male progeny of the genotype 
P[UAS-ErbB3&4*]/Cyo or P[UAS-ErbB3&4*]/TM3,Sb from this cross were mated to 
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each other to create the final stock. For insertions on the X chromosome (I)—one line 
from ErbB4, females harboring the transgene were mated by FM6, y w B males. Female 
progeny of the genotype P [UAS-ErbB4]/FM6, y w B were again mated to FM6, y w B 
males to create the final stock. 
 
Gain of Function Studies with the GAL4 System 
GaL4 system is the primary tool used for misexpression (gain of function) studies. In this 
system, a gene of interest can be expressed in a desired pattern using the mated 
combination of a “driver” (GAL4) and a “responder” (UAS) construct, as shown in 
Figure 4 below 
 
Figure 4: Summary of GAL4 misexpression system (taken from Duffy, 2002) 
The GAL4 gene is linked to a regulatory element, for example, one that expresses in the 
ovaries. As GAL4 is produced in this pattern, it will bind to the upstream activating 
sequence (UAS), which, if present, should initiate the transcription of the linked gene of 
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interest (Brand and Phelps, 1998). This is an ideal tool to use in misexpression studies, as 
it can regulate the expression of a gene both spatially and temporally. 
In the misexpression experiments, GAL4 drivers CY2 and GMR, which express in the 
ovaries and the eyes, respectively, were used for these studies. In all cases, 3-4 females 
with a GAL4 driver were mated to 2-3 males with a UAS-linked gene of interest. 
 
GFP Localization & Expression 
Larvae and Pupae from Cy2.GAL4 x P [UAS-ErbB3*] and GMR.GAL4 x P [UAS-
ErbB3*] variant matings were examined under a Zeiss Discovery fluorescent dissection 
microscope to determine each construct’s level of GFP expression. Images were then 
captured using a Zeiss Axiocam and were processed with Zeiss’s Axiovision software. 
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RESULTS 
 
 
Collection and Mapping of Transgenics 
For the first part of this project, transgenics were collected and mapped. ErbB3 
injected larvae produced a total of 63 G0s.   G0s were then screened for transgenic lines. 
From the screening process, 10 independent transgenics lines were identified, expanded 
and mapped. A record of these transgenic lines and their respective eye colors can be 
found in table 1 below. In order to detect the localization of the ErbB3 gene in the fly 
genome, flies were mapped to one of four possible fly chromosomes. All 10 lines mapped 
to either chromosome 2 or chromosome 3.  
 
Table 1: Mapped UAS-ErbB3 Transgenic lines 
Lines Eye Color Location  
(Chromosome) 
ARB6F-1M  Orange 2 
ARB10F-1M Light Yellow 3 
ARB22F-1M Deep Orange 3 
ARB31F-1M Orange 3 
ARB32M-1M Yellow 2 
ARB48M-1M Orange  
ARB50M-1M Orange 3 
ARB53M-1M Orange 3 
ARB55M-1M Orange 3 
 
 
 
 
 
 
 
 
Independent   
Lines 
ARB15F-1M Orange 2 
ARB31F-2M Orange  3 
ARB32M-2M Light yellow  2 
ARB48M-2M Orange 2 
Back-Up  
Lines 
ARB50M-2M Yellow 2 
 ARB53M-2M Orange 3 
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The same process was repeated for ErbB4. 65 G0s were produced from ErbB4 
injected larvae. Unlike ErbB3, the screening process for ErbB4 was very tedious but 
efficient. A total of three transgenic flies were obtained but. These lines mapped to either 
chromosomes 1, 2, and 3, giving more variety than ErbB3.  A record of these transgenic 
lines, respective eye colors and mapping results can be seen in table 2 below. 
 
Table 2: Mapped UAS-ErbB4 Transgenic lines 
Lines Eye Color of 
Transgenic 
Chromosome Gene 
is Mapped To 
SAA14F-1M Yellow 1  
SAB13M-1F Orange 3 
 
Independent Lines 
SAB17F-1M Orange 2 
SAB13M-2F Orange 3 Back-up lines 
SAB17F-1F Orange 2 
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Expression and Localization of GFP 
For the second part of this project, larvae and pupae of select ErbB3 and ErbB4 
transgenic lines were checked for expression and localization of GFP after crossing with 
GMR-GAL4 and CY2-GAL4. GFP expression was detected in both ErbB family 
members. However, expression in ErbB4 lines appeared much higher than in ErbB3 lines 
as depicted by figures 4 and 5 below. From crossing GMR- GAL4 and CY2-GAL4 with 
ErbB4 lines, GFP expression was detected in both the larvae and Pupae. In ErbB4 lines, 
CY2-GAL4 driven GFP expression was detected in salivary glands and cell clusters 
along the sides of larvae and pupae. In ErbB3 equivalent lines however, GFP expression 
was only detected in the salivary glands, suggesting that higher levels of GFP expression 
in ErbB4 than in ErbB3 (figure 4). This expression pattern was further confirmed by 
results from GMR-GAL4 driven expression. GFP expression was detected in the eye 
tissue of ErbB4 but not ErbB3 lines. This result is depicted in figure 5. A summary table 
of the expression results is presented in table 3.      
 
Table 3: GFP Expression Analysis of Select UAS-ErbB3 & UAS-ErbB4 
Lines Expression with 
CY2 
Expression with 
GMR 
ARB22F-1M Yes No 
 
UAS-ErbB3 lines 
ARB50M-1M Yes No 
SAB13M-1F Yes Yes  
UAS-ErbB4 lines SAB17F-1M Yes Yes 
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 Figure 4: GFP Expression in Larvae and Pupae of ErbB3 and ErbB4—CY2 Driver. GFP 
 Expression detected in larvae/pupa of ErbB receptors. Expression detected in salivary gland of 
 ErbB3 and ErbB4. 
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 Figure 5: GMR driven GFP Expression in Pupae of ErbB4 using different filters. GFP 
 expression detected in pupae of ErbB4 (Filters 1 and 2 represent two different filter sets for 
 visualizing GFP). 
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Functionality 
Most critically, functionality of the ErbB3 and ErbB4 transgenes was tested by observing 
phenotypes of adult progeny from the CY2-GAL4 and GMR-GAL4 driver crosses. In 
ErbB4, adult flies from GMR-GAL4 crosses showed roughness and loss of eye tissue. 
This was not the case for ErbB3, which showed a similar phenotype to w1118 ,  the 
control. A depiction of the GMR-GAL4 effects for ErbB4 can be seen in figure 6 below. 
With respect to CY2-GAL4 driver crosses, ErbB4 flies did not make it past their pupae 
and larval stages, suggesting lethality. In contrast, ErbB3 flies with CY2-GAL4 showed 
GFP expression in ovaries. No abnormal phenotypic effects were detected in these ErbB3 
lines however.   
 
  
 
 
Figure 6: Misexpression of ErbB4 results in a 
rough eye. 
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DISCUSSION 
 
One of the long-term objectives of the Duffy lab is to develop simple phenotypic 
assays in Drosophila that could be used for screening chemical libraries for small 
molecule inhibitors of the EGFR family of Receptor Tyrosine Kinases. To achieve this 
long term objective, the goal of this MQP was to generate transgenic Drosophila 
expressing GFP tagged versions of the human EGFR family members, ErbB3 and ErbB4, 
and test them for functionality. Previously in the lab, work had been done to express the 
human EGFR (ErbB1) and demonstrate functionality in both oogenesis (as indicated by 
dorsalized chorions) and eye development (observed by the presence of a rough eye).  
This preliminary work also indicated that the activity of hEGFR could be inhibited by 
known tyrosine kinase inhibitors.  Here I extend this work and report the development of 
transgenic lines for ErbB3 and ErbB4. 
 
Generation of Transgenic Lines 
For ErbB3 10 independent transgenic lines were generated, mapped, and stable stocks 
created.  For ErbB4 3 independent lines were generated, mapped and setting up stable 
stocks for ErbB4 is in progress.   
 
Expression and Localization of ErbB3&4 receptors 
For both sets of transgenic lines, GFP expression was detected and appeared to 
demonstrate normal membrane localization of the receptors.  This strongly suggests that 
the C-terminal GFP tag does not interfere with localization of the tagged receptors to the 
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membrane.  However, of note, ErbB3 expression levels generally appeared weaker than 
ErbB4 levels, as depicted in larval pictures from figure 4.  
 
Functionality of ErbB3&4 receptors 
Both transgenic lines were also tested for activity through misexpression phenotypes in 
the developing eye and during oogenesis using the GAL4/UAS system. In ErbB3, no 
misexpression phenotypes were observed in the eyes and ovaries. For ErbB4 
misexpression in the eye led to a robust phenotype.  Eyes of transgenic flies 
misexpressing ErbB4 were small, irregular and rough as compared to that of wild type or 
flies expressing GMR-GAL4 alone. Consistent with high levels of activity, misexpression 
of ErbB4 with CY2-GAL4 led to significant lethality and therefore I was unable to 
examine for effects during oogenesis. This supports the prevailing hypothesis that ErbB4 
can activate the Drosophila EGFR signaling pathway, but ErbB3 is only active upon 
dimerizing with other ErbB family members. My results, however, do suggest that ErbB3 
does not interact/dimerize with the Drosophila EGFR and if so may not be capable of 
binding to downstream adaptors as shown below figure 7   
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Figure 7: The tyrosine residues on the ErbB and dEGFR tails.  Conserved sequences, shown in purple, 
appears responsible for the binding to a SH2 domain, such as is found in Grb2 protein.  The second set, 
shown in green, appears responsible for the binding of a PTB domain, such as is found in Shc.  The 
colored, boxed regions on the tail show conserved tyrosine residues and their location in the receptor 
sequence.  The related consensus sequences and the potential molecules that bind to the phosphorylated 
tyrosines are shown on the left side of the figure.  The dashes in the tail show the tyrosine residues that 
were not conserved (Taken from: Leduc, 2007) 
 
 
Based on the work of Leduc, 2007, indicating that hEGFR/ErbB1, ErbB2, and 
ErbB4, but not ErbB3 contain conserved tyrosines in their cytoplasmic tail (figure 7), we 
would predict that they and not ErbB3 would be capable of activating the downstream 
components of signaling in Drosophila.  Consistent with this hypothesis my work showed 
that indeed ErbB3 appears to have no activity on its own.  However, it is also consistent 
with prevailing notion in field that it needs to dimerize with another member of the 
family for activity. To determine if ErbB3 lacks activity because of lack of an appropriate 
kinase partner or the absence of conserved tyrosines it will be necessary to combine the 
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ErbB3 transgene with ErbB2 or other receptors.  Experiments to test this are currently 
underway in the lab.   
In contrast, as predicted by the single conserved tyrosine that acts as a binding site 
for Grb2, ErbB4 appears to have significant activity.  Misexpression in the eye resulted in 
strong rough eye phenotypes and in the some lines resulted in larval/pupal lethality.  This 
suggests that GFP-tagged ErbB4 is active in vivo in Drosophila and therefore its 
misexpression phenotypes, as with hEGFR, could provide a means to screen for novel 
ErbB family based therapeutics and ultimately better treatments for EGFR based cancers.   
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